Issue 155

Psych Capital completes acquisition of Shortwave Pharma

Global investment firm Psych Capital has announced the completion of its 100% acquisition of life science company Shortwave Pharma, which is developing breakthrough therapies to address unmet medical needs in mental health, particularly in the field of eating disorders.

Shortwave Pharma’s clinical programme is developing a transformative solution for anorexia nervosa, the most fatal eating disorder, and a complex and often underserved area of healthcare – designing a novel delivery method and drug combination with an expanded mechanism of action specifically designed to address the requirements of this vulnerable population.

William Potts, Chief Investment Officer of Psych Capital Plc, emphasised the importance of this acquisition, stating: “Shortwave Pharma has the potential to positively impact millions of patients all over the world who have very serious unmet needs and we’re thrilled to start a very exciting journey together.”

EXTENDED DMT ADMINISTRATION SAFE AND WELL TOLERATED

A study from the Centre for Psychedelic Research at Imperial College London has shown that extended DMT IV infusions are safe and well tolerated.

The single-blind, placebo-controlled study utilised a novel method of DMT administration which took the form of a bolus injection paired with a constant-rate infusion – providing more precise control over dosing.

PSILOCYBIN FOR CANCER-RELATED DEPRESSION

Sunstone Therapies has announced the start of its first study investigating multiple doses of psilocybin in the treatment of major depression disorder (MDD) in patients with cancer.

The Phase 2 study, taking place at Bill Richards Center for Healing at the Aquilino Cancer Center, will examine the safety and efficacy of up to two 25mg doses of psilocybin administered at an interval of 9 to 10 weeks.

BUSINESS AND INVESTMENT

Psyence Production – a division of Psyence – has announced it has increased its production capabilities through the design of a new laboratory.

PharmaDrug has announced the completion of its acquisition of private pharmaceutical research and development company Securedose Synthetics.

PharmAla has completed its first shipment of MDMA and psilocybin to Cortexa, Australia, its 50:50 Australian Joint Venture with Vitura Health Limited.

Reset Pharma has confirmed it has received Notice of Safe to Proceed from FDA for an Investigational New Drug (IND) Application for Oral Psilocybin RSTP1000.

Would your organisation benefit from engaging Europe's psychedelic medicine community?

Partnership with Psychedelic Health provides the opportunity to engage an audience ready to support the development of psychedelic medicine.

For more information and to request the media kit, please email stephanie@psych.global

REQUEST MEDIA KIT

SCIENCE AND RESEARCH

Researchers at Duke University are investigating psychedelics by using hallucinogenic fish to learn how they function in the brain.

Enveric Biosciences has received a Notice of Allowance (NoA) from USPTO for a patent application involving EB-373, the company’s NCE prodrug of psilocin.

A clinical trial has launched in San Diego that will examine the preliminary effectiveness of MDMA-facilitated bCBCT for improving chronic PTSD.

The Washington Post explores how psychedelics may help with climate anxiety – a problem that mental health professionals say is increasing.

REGULATION AND LEGISLATION

The Boston Globe reports that a group of campaigners has collected more than 75,000 signatures on a ballot initiative that seeks to legalise psilocybin.

Minesotta’s Psychedelic Medicine Task Force held its first meeting which set out the Force’s work for the coming months as well as selecting a chariperson.

ARTICLES OF INTEREST

The UK Government has not included the Mental Health Bill in the King’s Speech, drawing criticism from mental health charities.

University researchers are calling for better integration of mental health and alcohol services among minority ethnic groups.